British pharmaceuticals group AstraZeneca has approached US rival Gilead Sciences over a possible record merger, Bloomberg reported, as the pair spearhead treatments for Covid-19. AstraZeneca informally contacted Gilead last month, Sunday’s report said, adding that a combined group would be worth a record-breaking US$236 billion when taking into account the companies’ closing valuations Friday. That was […]
Thank you for registering!
An account was already registered with this email. Please check your inbox for an authentication link.